( ill advance in the clinical trials proc...)Acuity One-Year Findings Meet All Primary Endpoints in Favor of,Angiomax (Bivalirudin) Alone Treatment Group,Health

ill advance in the clinical trials process, whether clinical trial results will warrant submission of applications for regulatory approval, whether the Company will be able to obtain regulatory approval for additional indications of Angiomax and such other factors as are set forth in the risk factors detailed from time to time in the Company's periodic reports and registration statements filed with the Securities and Exchange Commission including, without limitation, the risk factors detailed in the Company's Quarterly Report on Form 10-K filed on March 1, 2007, which are incorporated herein by reference. The Company specifically disclaims any obligation to update these forward-looking statements.

CONTACT: Media - Kelly Lindenboom Biosector 2 212-845-5622 Investors - Michael Mitchell Executive Director,Corporate Affairs The Medicines Company 973-656-1616 klindenboom@biosector2.com investor.relations@themedco.com

Web site: http://www.themedicinescompany.com/http://www.angiomax.com/

Ticker Symbol: (NASDAQ-NMS:MDCO)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company

'"/>




Page: 1 2 3 4 5 6
Related medicine technology :

1. New One-Year Pharmacoeconomic Study Shows Avonex is Cost-Effective Relative to Other Interferon Therapies for Multiple Sclerosis
2. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
4. Molecular Target of Bradmers Neuradiab Further Validated by Independent Findings
5. Anacor Identifies a Novel Mechanism for Its Lead Anti-Fungal Drug, AN2690; Findings Published in Science
6. Advanced Viral Research Corp. Announces Positive Preliminary Findings from Ongoing Phase II Dermatological Study
7. Haemacure Announces Preliminary Findings of its Plasma Discard Analysis
8. EPIX Pharmaceuticals Presents Findings from PRX-00023 Phase 3 Clinical Trial at 47th Annual NCDEU Meeting
9. Lexicon Pharmaceuticals and Fox Chase Publish Findings on Immune Deficiency
10. Prana Biotechnology Presents New Key Findings on PBT2
11. Investigation Findings, Corroborated by Empirical Evidence of the Schisandra Berry as Cardio-Tonic in Traditional Chinese Medicine for Hundreds of Years, Support the Use of Schisandrin B in the Prevention and Treatment of IHD